RETRACTED: Cardiovascular outcomes of ethyl eicosapentaenoic acid in diabetes mellitus: A meta-analysis.
Ann Med Surg (Lond)
; 84: 104846, 2022 Dec.
Article
em En
| MEDLINE
| ID: mdl-37034272
ABSTRACT
Background:
We aim to conduct a comprehensive meta-analysis encompassing all studies to assess the efficacy of Vascepa in patients with diabetes mellitus (DM) in preventing or treating existing coronary artery disease (CAD).Methods:
Digital databases were queried. Odds ratios (OR) were calculated for the followingoutcomes:
composite outcome, all-cause mortality, and cardiovascular mortality.Results:
A total of 4 randomized control trials (33,092 patients; Vascepa n = 16586; Placebo n = 16506) were included in our analysis. The overall mean age was 64.3 years old (Vascepa = 64.3 years; Placebo = 64.3 years). The sample was 61.5% male (Vascepa = 60.8%; Placebo = 62.1%). In patients with DM, Vascepa was found to have no significant effect on the primary composite outcome (OR 0.97, 95%CI 0.91-1.04, p > 0.05), all-cause mortality (OR 0.96, 95%CI 0.90-1.03, p > 0.05), and cardiovascular mortality (OR 0.90, 95%CI 0.74-1.10, p > 0.05). Subgroup analysis by Vascepa type and treatment type was similarly non-significant.Conclusion:
Our study concluded that Vascepa did not affect cardiovascular outcomes in patients with DM.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
/
Systematic_reviews
Idioma:
En
Revista:
Ann Med Surg (Lond)
Ano de publicação:
2022
Tipo de documento:
Article